[go: up one dir, main page]

DE10290025T1 - Verfahren zur Differenzierung von Stammzellen in Insulin-produzierende Zellen - Google Patents

Verfahren zur Differenzierung von Stammzellen in Insulin-produzierende Zellen

Info

Publication number
DE10290025T1
DE10290025T1 DE10290025T DE10290025T DE10290025T1 DE 10290025 T1 DE10290025 T1 DE 10290025T1 DE 10290025 T DE10290025 T DE 10290025T DE 10290025 T DE10290025 T DE 10290025T DE 10290025 T1 DE10290025 T1 DE 10290025T1
Authority
DE
Germany
Prior art keywords
insulin
procedure
cells
differentiating stem
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE10290025T
Other languages
English (en)
Inventor
Luc St-Onge
Ursula Hoffmann
Anna M Wobus
Przemyslaw Blyszczuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen Aktiengesellschaft 37079 Goettingen De
Institut fuer Pflanzengenetik und Kulturpflanzenforschung
Original Assignee
Institut fuer Pflanzengenetik und Kulturpflanzenforschung
Develogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut fuer Pflanzengenetik und Kulturpflanzenforschung, Develogen AG filed Critical Institut fuer Pflanzengenetik und Kulturpflanzenforschung
Publication of DE10290025T1 publication Critical patent/DE10290025T1/de
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073Stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/39Pancreas; Islets of Langerhans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0676Pancreatic cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507Pancreatic cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/04Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from germ cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/62Insulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
DE10290025T 2001-04-19 2002-04-19 Verfahren zur Differenzierung von Stammzellen in Insulin-produzierende Zellen Ceased DE10290025T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28453101P 2001-04-19 2001-04-19
PCT/EP2002/004362 WO2002086107A2 (en) 2001-04-19 2002-04-19 A method for differentiating stem cells into insulin-producing cells

Publications (1)

Publication Number Publication Date
DE10290025T1 true DE10290025T1 (de) 2003-10-09

Family

ID=23090548

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10290025T Ceased DE10290025T1 (de) 2001-04-19 2002-04-19 Verfahren zur Differenzierung von Stammzellen in Insulin-produzierende Zellen

Country Status (5)

Country Link
US (1) US20050054102A1 (de)
EP (1) EP1379626A2 (de)
JP (1) JP2004527249A (de)
DE (1) DE10290025T1 (de)
WO (1) WO2002086107A2 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
GB2415432B (en) * 2001-12-07 2006-09-06 Geron Corp Islet cells from human embryonic stem cells
JPWO2003087349A1 (ja) * 2002-04-17 2005-08-18 大塚製薬株式会社 間葉系細胞から膵β細胞を形成する方法
US20060003446A1 (en) * 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
EP2361966A1 (de) * 2002-05-17 2011-08-31 Mount Sinai School of Medicine of New York University Zellen von Mesoderm und vom entgültigen Endoderm
AU2003302702B2 (en) * 2002-12-05 2008-08-07 Technion Research & Development Foundation Ltd. Cultured human pancreatic islets, and uses thereof
JP5426073B2 (ja) 2003-05-08 2014-02-26 セルアーティス アーベー ヒト胚盤胞由来幹細胞(hBS細胞)のフィーダー支持からフィーダーなしの培養系への効率的な移送方法
US20070037281A1 (en) * 2003-06-23 2007-02-15 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Method for differentiating stem cells in cells that produce a pancreatic hormone
US7875273B2 (en) 2004-12-23 2011-01-25 Ethicon, Incorporated Treatment of Parkinson's disease and related disorders using postpartum derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
ES2542069T3 (es) 2003-06-27 2015-07-30 DePuy Synthes Products, Inc. Regeneración y reparación de tejido neural usando células del postparto derivadas del cordón umbilical
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
EP1644027B1 (de) * 2003-07-16 2014-04-09 Evotec International GmbH Verwendung von pleiotrophin zur behandlung von bauchspeicheldrüsenkrankheiten, fettsucht und metabolischem syndrom
EP1689321B1 (de) * 2003-11-07 2017-01-04 The University of Connecticut Künstliche gewebesysteme und ihre verwendungen
US20080241106A1 (en) * 2003-11-27 2008-10-02 Matthias Austen Method for Preventing and Treating Diabetes Using Neurturin
WO2005083059A1 (en) * 2004-02-23 2005-09-09 University Of Florida Compositions and methods for making insulin-producing cells
DE102004017484B4 (de) 2004-04-08 2006-07-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung einer biologischen Materialzusammensetzung tierischen Ursprungs
DE102004017476B4 (de) 2004-04-08 2009-03-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung einer Epithelzellen enthaltenden Zellzusammensetzung
CA2576573A1 (en) * 2004-08-11 2006-02-16 Universite De Geneve Use of pax4 in pancreatic cell proliferation
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
WO2006074308A2 (en) * 2005-01-07 2006-07-13 Wake Forest University Health Sciences Regeneration of pancreatic islets by amniotic fluid stem cell therapy
WO2006083782A2 (en) * 2005-01-31 2006-08-10 Es Cell International Pte Ltd. Directed differentiation of embryonic stem cells and uses thereof
WO2006108651A2 (en) * 2005-04-12 2006-10-19 Develogen Aktiengesellschaft Use of activin products for preventing and treating diabetes and/or metabolic syndrome
EP1885454A2 (de) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Verwendung von gsk-3-hemmern zur prävention und behandlung von pankreatischen autoimmunkrankheiten
US7968535B2 (en) 2005-05-04 2011-06-28 Develogen Atkiengesellschaft Use of azapaullones for preventing and treating pancreatic autoimmune disorders
EP1728873A1 (de) 2005-05-30 2006-12-06 DeveloGen Aktiengesellschaft Verwendung einer Insulinomazelle zum Nachweis von Mitogenen von pankreatischen Beta-Zellen
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
PT1888123E (pt) * 2005-06-08 2013-03-13 Janssen Biotech Inc Uma terapêutica celular para a degeneração ocular
EP1893746A2 (de) * 2005-06-13 2008-03-05 Novo Nordisk A/S Modulation von zellen
ES2642844T3 (es) 2005-12-16 2017-11-20 DePuy Synthes Products, Inc. Composiciones y métodos para inhibir una respuesta inmune adversa en el trasplante de histocompatibilidad que no coinciden
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US8415153B2 (en) 2006-06-19 2013-04-09 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
MX2010001335A (es) 2007-07-31 2010-06-02 Lifescan Inc Diferenciacion de celulas madre embrionarias humanas.
KR20090051695A (ko) * 2007-11-19 2009-05-22 배용석 췌도 주변세포를 인슐린을 분비할 수 있는 세포로 분화시키는 방법
ES2372463T3 (es) * 2007-11-27 2012-01-20 Lifescan, Inc. Diferenciación de células madre embrionarias humanas.
CN102046779A (zh) 2008-02-21 2011-05-04 森托科尔奥索生物科技公司 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物
US8623648B2 (en) * 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
CA2723820A1 (en) * 2008-05-09 2009-11-12 Vistagen Therapeutics, Inc. Pancreatic endocrine progenitor cells derived from pluripotent stem cells
US20110091971A1 (en) * 2008-06-30 2011-04-21 Janet Davis Differentiation of Pluripotent Stem Cells
JP5734183B2 (ja) 2008-06-30 2015-06-17 ヤンセン バイオテツク,インコーポレーテツド 多能性幹細胞の分化
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
CN102272291B (zh) 2008-10-31 2018-01-16 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
RU2528861C2 (ru) * 2008-10-31 2014-09-20 Сентокор Орто Байотек Инк. Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток
AU2009316580B2 (en) 2008-11-20 2016-04-14 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
MX2011005289A (es) * 2008-11-20 2011-06-01 Centocor Ortho Biotech Inc Metodos y composiciones para union y cultivo celular sobre sustratos planares.
ES2665883T3 (es) 2008-12-19 2018-04-30 DePuy Synthes Products, Inc. Tratamiento de enfermedades y trastornos pulmonares y pulmonares
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
SG174551A1 (en) 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
WO2011011349A2 (en) * 2009-07-20 2011-01-27 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
JP6219568B2 (ja) 2009-07-20 2017-10-25 ヤンセン バイオテツク,インコーポレーテツド ヒト胚性幹細胞の分化
JP5819825B2 (ja) * 2009-07-20 2015-11-24 ヤンセン バイオテツク,インコーポレーテツド ヒト胚性幹細胞の分化
MX339669B (es) * 2009-12-23 2016-06-02 Janssen Biotech Inc Diferenciacion de celulas madres embrionarias humanas.
RU2701335C2 (ru) * 2009-12-23 2019-09-25 Янссен Байотек, Инк. Способ получения популяции панкреатических эндокринных клеток, соэкспрессирующих nkx6.1 и инсулин, и способ лечения диабета
BR112012022145A2 (pt) 2010-03-01 2020-10-06 Janssen Biotech, Inc. métodos para purificar células derivadas de células-tronco pluripotentes
KR101986176B1 (ko) 2010-05-12 2019-06-05 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
EP2611910B1 (de) 2010-08-31 2018-01-17 Janssen Biotech, Inc. Differenzierung menschlicher embryonischer stammzellen
RU2673946C1 (ru) 2010-08-31 2018-12-03 Янссен Байотек, Инк. Дифференцирование плюрипотентных стволовых клеток
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
JP6051378B2 (ja) * 2011-05-02 2016-12-27 国立大学法人 熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
CA2860107C (en) 2011-12-22 2021-06-01 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
SG11201403465PA (en) 2011-12-23 2014-10-30 Atrm Llc Detection of human umbilical cord tissue-derived cells
HK1206058A1 (en) 2012-03-07 2015-12-31 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
ES2897649T3 (es) 2012-06-08 2022-03-02 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
HK1217727A1 (zh) 2012-12-31 2017-01-20 Janssen Biotech, Inc. 用於分化成胰腺內分泌細胞的人多能細胞的懸浮和群集
EP4219683A1 (de) 2012-12-31 2023-08-02 Janssen Biotech, Inc. Differenzierung humaner embryonaler stammzellen in endokrine pankreaszellen mittels hb9-regulatoren
EP2938724B1 (de) 2012-12-31 2020-10-28 Janssen Biotech, Inc. Kultivierung von menschlichen embryonalen stammzellen an der luft-flüssigkeitsgrenze zur differenzierung in endokrine pankreaszellen
US10405961B2 (en) 2013-03-14 2019-09-10 Cell and Molecular Tissue Engineering, LLC Coated surgical mesh, and corresponding systems and methods
US10130288B2 (en) 2013-03-14 2018-11-20 Cell and Molecular Tissue Engineering, LLC Coated sensors, and corresponding systems and methods
DK3143127T3 (da) 2014-05-16 2021-09-13 Janssen Biotech Inc Anvendelse af små molekyler til at forstærke mafa-ekspression i endokrine pankreasceller
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11834680B2 (en) 2017-06-28 2023-12-05 Rutgers, The State University Of New Jersey Single kidney cell-derived organoids
WO2019204750A1 (en) * 2018-04-20 2019-10-24 Cellino Biotech, Inc. Directed cell fate specification and targeted maturation
EP3877748A4 (de) 2018-11-06 2022-11-09 Cellino Biotech, Inc. Systeme zur zellkontrolle
CN116064676B (zh) * 2022-08-24 2024-12-13 深圳市沃英达生命科学有限公司 CRISPRa介导的间充质干细胞制备胰岛素分泌细胞的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
CA2392615A1 (en) * 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
US20020115059A1 (en) * 2000-10-26 2002-08-22 Naohiro Terada Drug screening system
JP2005503759A (ja) * 2001-01-24 2005-02-10 アメリカ合衆国 幹細胞の膵臓内分泌細胞への分化方法

Also Published As

Publication number Publication date
EP1379626A2 (de) 2004-01-14
US20050054102A1 (en) 2005-03-10
JP2004527249A (ja) 2004-09-09
WO2002086107A2 (en) 2002-10-31
WO2002086107A3 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
DE10290025T1 (de) Verfahren zur Differenzierung von Stammzellen in Insulin-produzierende Zellen
DE60207148D1 (de) Vorrichtung und Verfahren zur Gewinnung von Zellen
DE60326730D1 (de) Verfahren zur proteinverabreichung in zellen
DE60128253D1 (de) Precursor-lösungen und verfahren zur ihrer verwendung
DE60132554D1 (de) STATORBLECHKöRPER UND VERFAHREN ZUR HERSTELLUNG DESSELBEN
DE50107437D1 (de) Verfahren zur herstellung von polyacrylaten
DE60228067D1 (de) Verfahren zur differenzierung mesenchymaler stammzellen zu nervenzellen
ATE419260T1 (de) C-aryl-glucosid-sglt2-inhibitoren und verfahren zu ihrer herstellung
DE60233058D1 (de) Silsesquioxanderivate und verfahren zu ihrer herstellung
DE60130836D1 (de) Architektur und Verfahren zur Kontextumschaltung
DE60138344D1 (de) Verfahren zur Mutagenese
DE60125366D1 (de) Perfluorpolyether und verfahren zur ihrer herstellung
ATE440944T1 (de) Vorrichtung zur vorbereitung von zellen
ATE427666T1 (de) Saure protein- und ballaststoffhaltige zusammensetzungen und verfahren zu ihrer herstellung
DE60134540D1 (de) Töchiometrie aufweisender isolierschicht und verfahren zur herstellung
DE60138201D1 (de) Fraktioniertes sojabohnenprotein sowie verfahren zur herstellung desselben
DE60213444D1 (de) Fluorpolymerlaminate und verfahren zur herstellung derselben
DE60238014D1 (de) Nichtwässrige-Sekundärbatterie und Verfahren zur deren Herstellung
DE60139489D1 (de) Zusammensetzungen und verfahren zur reinigung von kontaktlinsen
DE502004005149D1 (de) Fräsverfahren zur fertigung von bauteilen
DE502004007952D1 (de) Fräsverfahren zur fertigung von bauteilen
DE60141586D1 (de) Verfahren zur fertigungssteuerung
DE50113292D1 (de) Verfahren zur abreicherung von endotoxinen
ATE321832T1 (de) Verfahren zur aufbereitung von oliven
DE50103096D1 (de) Verfahren zur herstellung von tensidgranulaten

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law

Ref document number: 10290025

Country of ref document: DE

Date of ref document: 20031009

Kind code of ref document: P

8127 New person/name/address of the applicant

Owner name: DEVELOGEN AKTIENGESELLSCHAFT, 37079 GOETTINGEN, DE

Owner name: INSTITUT FUER PFLANZENGENETIK UND KULTURPFLANZENFOR

8131 Rejection